Mendole extends long-stop date for Rebo acquisition to Dec. 1, 2026
Bitget2026/10/08 13:39Mendole extended the long-stop date to complete its planned acquisition of Rebo to Dec. 1, 2026. The previous long-stop date under the share purchase agreement was Sept. 15, 2026. Debt financing for the deal lapsed, prompting continued talks with Rebo’s sellers on completing the transaction. Mendole is working to secure new financing for the acquisition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mendole A/S published the original content used to generate this news brief via Cision (Ref. ID: 20261008:BIT:0852:0) on October 08, 2026, and is solely responsible for the information contained therein.
- Mendole extended the long-stop date to complete its planned acquisition of Rebo to Dec. 1, 2026.
- The previous long-stop date under the share purchase agreement was Sept. 15, 2026.
- Debt financing for the deal lapsed, prompting continued talks with Rebo’s sellers on completing the transaction.
- Mendole is working to secure new financing for the acquisition.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
